We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular POC Market to Reach USD 510 Million by 2023

By LabMedica International staff writers
Posted on 27 Feb 2018
The molecular point-of-care market (POC), consisting of systems with molecular capability used in decentralized test environments, was worth an estimated USD 165 million in 2017 and is expected to continue growing in the double-digits to reach USD 510 million in 2023.

The key growth areas in molecular POC diagnostics are expected to be influenza testing, hospital-acquired infections and sexually transmitted diseases. More...
Pricing remains a challenge for molecular systems, although the advantages they offer paint a bright long-term outlook for the market. PCR or sequencing based systems in decentralized settings are expected to grow at the fastest pace, in terms of revenue, as compared to other IVD market categories.

These are the latest findings of Kalorama Information, (New York, NY, USA), an independent medical market research firm.

Molecular point-of-care solutions now offer multiplexing capabilities, allowing an assay to detect multiple pathogenic targets for an infectious condition, in a single run. Multiplex assays for respiratory infections are more common, targeting multiple flu viruses and strains as well as respiratory syncytial virus, among others. Test panels are available for detecting multiple possible causes of gastrointestinal infection, sepsis, or even multiple tropical disease agents such as Ebola, Dengue, Chikungunya, malaria, and so on. It is also possible to design assays for targeting specific genes generally associated with non-infectious diseases such as cancer or Alzheimer's disease, or to determine a patient's sensitivity or resistance to pharmaceutical treatments.

According to Kalorama, influenza and respiratory is the key area of molecular POC diagnostics with a share of almost 40% and is expected to continue dominating the market until 2023. However, immunoassay POC has not exhibited a visible decline in revenue growth and continues to witness innovations. Even in influenza testing, which is the mainstay of molecular POC testing, immunoassay has not witnessed a decline from the presence of molecular testing.

"Just as when molecular test systems were first introduced, huge predictions settled down to reasonable ones, 15 years ago, so it is with the point of care version." said Bruce Carlson, Publisher of Kalorama Information. "This is a market with high potential and investor interest was justified, but healthcare organizations are judicious about purchasing and the technology will have to prove. There's also side benefits to these technologies, where large IVD players can present the system as complete package of laboratory equipment, down to POC level and that should continue to benefit the major players in molecular POC."

Related Links:
Kalorama Information


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.